FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912130462> ?p ?o ?g. }

• W2912130462 endingPage "643" @default.
• W2912130462 startingPage "637" @default.
• W2912130462 abstract "We conducted a single-arm phase II trial to evaluate the efficacy and adverse effects (AEs) of an anti-epidermal growth factor receptor monoclonal antibody, nimotuzumab, combined with cisplatin and 5-fluorouracil (PF) as first-line treatment in recurrent metastatic nasopharyngeal carcinoma after radical radiotherapy.Patients who met the eligibility criteria were recruited from ten institutions (ClinicalTrials.gov; NCT01616849). A Simon optimal two-stage design was used to calculate the sample size. All patients received weekly nimotuzumab (200 mg) added to cisplatin (100 mg/m2 D1) and 5-fluorouracil (4 g/m2 continuous infusion D1-4) every 3-weekly for a maximum of six cycles. Primary end point was objective response rate (ORR). Secondary end points included disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and AEs.A total of 35 patients were enrolled (13 in stage 1 and 22 in stage 2). Overall ORR and DCR were 71.4% (25/35) and 85.7% (30/35), respectively. Median PFS and OS were 7.0 (95% CI 5.8-8.2) months and 16.3 (95% CI 11.4-21.3) months, respectively. Unplanned exploratory analyses suggest that patients who received ≥2400 mg nimotuzumab and ≥4 cycles of PF had superior ORR, PFS and OS than those who did not (88.9% versus 12.5%, P < 0.001; 7.4 versus 2.7 months, P = 0.081; 17.0 versus 8.0 months, P = 0.202). Favourable subgroups included patients with lung metastasis [HROS 0.324 (95% CI 0.146-0.717), P = 0.008] and disease-free interval of >12 months [HROS 0.307 (95% CI 0.131-0.724), P = 0.004], but no difference was observed for metastatic burden. The only major grade 3/4 AE was leukopenia (62.9%).Combination nimotuzumab-PF chemotherapy demonstrates potential efficacy, and is well tolerated as first-line chemotherapy regimen in recurrent metastatic nasopharyngeal carcinoma." @default.
• W2912130462 created "2019-02-21" @default.
• W2912130462 creator A5011622378 @default.
• W2912130462 creator A5030095558 @default.
• W2912130462 creator A5030248136 @default.
• W2912130462 creator A5030841784 @default.
• W2912130462 creator A5033055387 @default.
• W2912130462 creator A5038296783 @default.
• W2912130462 creator A5038961648 @default.
• W2912130462 creator A5044497607 @default.
• W2912130462 creator A5045275586 @default.
• W2912130462 creator A5051633657 @default.
• W2912130462 creator A5060981506 @default.
• W2912130462 creator A5066073148 @default.
• W2912130462 creator A5078925966 @default.
• W2912130462 creator A5085198554 @default.
• W2912130462 creator A5086305933 @default.
• W2912130462 creator A5087898022 @default.
• W2912130462 creator A5090937408 @default.
• W2912130462 date "2019-04-01" @default.
• W2912130462 modified "2023-10-17" @default.
• W2912130462 title "Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial" @default.
• W2912130462 cites W1977966489 @default.
• W2912130462 cites W1981822576 @default.
• W2912130462 cites W1988890456 @default.
• W2912130462 cites W2004686162 @default.
• W2912130462 cites W2016208410 @default.
• W2912130462 cites W2029409133 @default.
• W2912130462 cites W2051061475 @default.
• W2912130462 cites W2052495315 @default.
• W2912130462 cites W2069789932 @default.
• W2912130462 cites W2094337557 @default.
• W2912130462 cites W2095617994 @default.
• W2912130462 cites W2112845420 @default.
• W2912130462 cites W2167030621 @default.
• W2912130462 cites W2240014735 @default.
• W2912130462 cites W2278160195 @default.
• W2912130462 cites W2305092094 @default.
• W2912130462 cites W2512237822 @default.
• W2912130462 cites W2890100090 @default.
• W2912130462 cites W4210983491 @default.
• W2912130462 cites W4293384264 @default.
• W2912130462 doi "https://doi.org/10.1093/annonc/mdz020" @default.
• W2912130462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30689735" @default.
• W2912130462 hasPublicationYear "2019" @default.
• W2912130462 type Work @default.
• W2912130462 sameAs 2912130462 @default.
• W2912130462 citedByCount "32" @default.
• W2912130462 countsByYear W29121304622020 @default.
• W2912130462 countsByYear W29121304622021 @default.
• W2912130462 countsByYear W29121304622022 @default.
• W2912130462 countsByYear W29121304622023 @default.
• W2912130462 crossrefType "journal-article" @default.
• W2912130462 hasAuthorship W2912130462A5011622378 @default.
• W2912130462 hasAuthorship W2912130462A5030095558 @default.
• W2912130462 hasAuthorship W2912130462A5030248136 @default.
• W2912130462 hasAuthorship W2912130462A5030841784 @default.
• W2912130462 hasAuthorship W2912130462A5033055387 @default.
• W2912130462 hasAuthorship W2912130462A5038296783 @default.
• W2912130462 hasAuthorship W2912130462A5038961648 @default.
• W2912130462 hasAuthorship W2912130462A5044497607 @default.
• W2912130462 hasAuthorship W2912130462A5045275586 @default.
• W2912130462 hasAuthorship W2912130462A5051633657 @default.
• W2912130462 hasAuthorship W2912130462A5060981506 @default.
• W2912130462 hasAuthorship W2912130462A5066073148 @default.
• W2912130462 hasAuthorship W2912130462A5078925966 @default.
• W2912130462 hasAuthorship W2912130462A5085198554 @default.
• W2912130462 hasAuthorship W2912130462A5086305933 @default.
• W2912130462 hasAuthorship W2912130462A5087898022 @default.
• W2912130462 hasAuthorship W2912130462A5090937408 @default.
• W2912130462 hasBestOaLocation W29121304621 @default.
• W2912130462 hasConcept C121608353 @default.
• W2912130462 hasConcept C126322002 @default.
• W2912130462 hasConcept C141071460 @default.
• W2912130462 hasConcept C143998085 @default.
• W2912130462 hasConcept C203092338 @default.
• W2912130462 hasConcept C2776055544 @default.
• W2912130462 hasConcept C2776694085 @default.
• W2912130462 hasConcept C2778496288 @default.
• W2912130462 hasConcept C2778997737 @default.
• W2912130462 hasConcept C2779438470 @default.
• W2912130462 hasConcept C2780456651 @default.
• W2912130462 hasConcept C31760486 @default.
• W2912130462 hasConcept C509974204 @default.
• W2912130462 hasConcept C535046627 @default.
• W2912130462 hasConcept C71924100 @default.
• W2912130462 hasConcept C90924648 @default.
• W2912130462 hasConceptScore W2912130462C121608353 @default.
• W2912130462 hasConceptScore W2912130462C126322002 @default.
• W2912130462 hasConceptScore W2912130462C141071460 @default.
• W2912130462 hasConceptScore W2912130462C143998085 @default.
• W2912130462 hasConceptScore W2912130462C203092338 @default.
• W2912130462 hasConceptScore W2912130462C2776055544 @default.
• W2912130462 hasConceptScore W2912130462C2776694085 @default.
• W2912130462 hasConceptScore W2912130462C2778496288 @default.
• W2912130462 hasConceptScore W2912130462C2778997737 @default.
• W2912130462 hasConceptScore W2912130462C2779438470 @default.
• W2912130462 hasConceptScore W2912130462C2780456651 @default.

• next